A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

April 19, 2022

Conditions
Diabetic Retinopathy
Interventions
DRUG

AKST4290

Oral AKST4290

DRUG

Placebo

Oral Placebo

Trial Locations (17)

29456

Site 127, Ladson

29902

Site 133, Beaufort

33761

Site 116, Clearwater

33880

Site 118, Winter Haven

34239

Site 117, Sarasota

60452

Site 120, Oak Forest

76012

Site 122, Arlington

77025

Site 134, Houston

77401

Site 130, Bellaire

77494

Site 129, Katy

78240

Site 128, San Antonio

78550

Site 126, Harlingen

84107

Site 125, Salt Lake City

85021

Site 132, Phoenix

85053

Site 136, Phoenix

91203

Site 123, Glendale

92647

Site 121, Huntington Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkahest, Inc.

INDUSTRY